2023
43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren R, Armstrong A, Imafuku S, Paul C, Kircik L, Colston E, Scharnitz T, Wang T, Banerjee S, Strober B. 43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program. Journal Of The American Academy Of Dermatology 2023, 89: ab147. DOI: 10.1016/j.jaad.2023.07.590.Peer-Reviewed Original Research
2020
Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis
Menter A, Blauvelt A, Strober B, Colombo M, Kisa R, Kundu S, Banerjee S, Leonardi C. Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. SKIN The Journal Of Cutaneous Medicine 2020, 4: s72. DOI: 10.25251/skin.4.supp.72.Peer-Reviewed Original ResearchBMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI
Gottlieb A, Strober B, Thaçi D, Gordon K, Kundu S, Kisa R, Wei L, Banerjee S, Merola J. BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. SKIN The Journal Of Cutaneous Medicine 2020, 4: s29. DOI: 10.25251/skin.4.supp.29.Peer-Reviewed Original Research